Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.75 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.59 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.59 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 8/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.40 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.40 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL5520318 | 0.96 | SLC7A5 (0.82) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL4011464 | 0.96 | SLC7A5 (0.82) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL5520323 | 0.96 | SLC7A5 (0.82) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL6129074 | 0.93 | SLC7A5 (0.64) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL5398677 | 0.91 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL6564498 | 0.91 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| D-Leucine SCHEMBL7676355 | 0.91 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL1585733 | 0.91 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL9007523 | 0.91 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 | |
| Leucine SCHEMBL11046268 | 0.91 | SLC7A5 (0.90) | SLC7A5SLC1A2SLC1A3SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | UAB RESEARCH FOUNDATION (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION (US) | 2021-10-21 | — | — | US | disclosed |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2021-06-29 | — | — | US | disclosed |
| US-11033535-B2 | Oxadiazoles and thiadiazoles as TGF-β inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3700545-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | Southern Research Institute (US) | 2020-09-02 | — | — | EP | disclosed |
| EP-3700522-A1 | OXADIAZOLES AND THIADIAZOLES AS TGF-BETA INHIBITORS | Southern Research Institute (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20200222371-A1 | OXADIAZOLES AND THIADIAZOLES AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION | 2020-07-16 | — | — | US | disclosed |
| US-10653682-B2 | Oxadiazoles and thiadiazoles as TGF-β inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2020-05-19 | — | — | US | disclosed |
| WO-2020033317-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2020-02-13 | — | — | WO | disclosed |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION | 2019-05-02 | — | — | US | disclosed |
| US-20190125730-A1 | OXADIAZOLES AND THIADIAZOLES AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION | 2019-05-02 | — | — | US | disclosed |
| US-9353149-B2 | Compounds, compositions and methods for the treatment of diseases through inhibiting TGF-β activity | SOUTHERN RESEARCH INSTITUTE (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2994156-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES THROUGH INHIBITING TGF- ACTIVITY | Southern Research Institute (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20140336115-A1 | Compounds, Compositions and Methods for the Treatment of Diseases Through Inhibiting TGF-ß Activity | SOUTHERN RESEARCH INSTITUTE (US) | 2014-11-13 | — | — | US | disclosed |
| WO-2014183018-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES THROUGH INHIBITING TGF-β ACTIVITY | SOUTHERN RESEARCH INSTITUTE (US) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11033535-B2 | Oxadiazoles and thiadiazoles as TGF-β inhibitors | SMAD3, TGFBR1, TGFBR2 | SLC7A5 3712/4885SLC1A2 3592/4885SLC1A3 3108/4885 |
| US-10653682-B2 | Oxadiazoles and thiadiazoles as TGF-β inhibitors | SMAD3, TGFBR1, TGFBR2 | SLC7A5 3712/4885SLC1A2 3592/4885SLC1A3 3108/4885 |
| US-20200222371-A1 | OXADIAZOLES AND THIADIAZOLES AS TGF-BETA INHIBITORS | SMAD3, TGFBR1, TGFBR2 | SLC7A5 3791/4885SLC1A2 3693/4885SLC1A3 3229/4885 |
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | TGFBR2, SMAD2, TGFB2 | SLC7A5 2993/4885SLC1A2 2850/4885SLC1A3 3756/4885 |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | TGFB1, TGFB2, SMAD3 | SLC7A5 2005/4885SLC1A2 2643/4885SLC1A3 1887/4885 |
| US-20140336115-A1 | Compounds, Compositions and Methods for the Treatment of Diseases Through Inhibiting TGF-ß Activity | TGFB1, TGFB2, TGFBR1 | SLC7A5 4481/4885SLC1A2 4612/4885SLC1A3 4721/4885 |
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | TGFBR2, SMAD2, TGFB2 | SLC7A5 2993/4885SLC1A2 2850/4885SLC1A3 3756/4885 |
| US-20190125730-A1 | OXADIAZOLES AND THIADIAZOLES AS TGF-BETA INHIBITORS | SMAD3, TGFBR1, TGFBR2 | SLC7A5 3791/4885SLC1A2 3693/4885SLC1A3 3229/4885 |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | TGFB1, TGFB2, SMAD3 | SLC7A5 2005/4885SLC1A2 2643/4885SLC1A3 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.